medigraphic.com
ISSN 1561-3070 (Digital)

2013, Número 3

<< Anterior Siguiente >>

Rev Cub Oftal 2013; 26 (3)


Nuevo esteroide tópico en el tratamiento del edema macular

Molina CC, Alemañy RE, Triana CI, González RL

Idioma: Español
Referencias bibliográficas: 46
Paginas: 452-456
Archivo PDF: 74.10 Kb.


RESUMEN

El pilar principal de tratamiento de las inflamaciones oculares tanto postquirúrgicas como endógenas, se basa en el uso de esteroides. Aunque estos medicamentos son efectivos, su empleo no está exento de riesgos como la hipertensión ocular y la aceleración de la formación de la catarata, principalmente en el caso de los esteroides más fuertes como la prednisolona y la betametasona. Esta revisión estuvo encaminada a la profundización del conocimiento sobre la bioquímica y el desarrollo del difluprednate, nueva droga esteroidea sintética de alta potencia, cuyo uso está aprobado por la Food and Drug Administration (FDA) para el tratamiento del edema macular después de la cirugía del segmento anterior. Se analizaron algunos aspectos de este medicamento off-label como la farmacocinética, el metabolismo, la distribución ocular del medicamento y utilidad en las fases I, II y III de ensayos clínicos sobre su utilización en pacientes con inflamaciones posoperatorias, tanto del segmento anterior como posterior y con uveítis anterior.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Apple DJ, Solomon KD, Tetz MR, Assia EI, Holland EY, Legler UF, et al. Posterior capsule opaciûcation. Surv Ophthalmol. 1992;37(2):73-116.

  2. Miyake K, Maekubo K, Miyake Y, Nishi O. Pupillary ûbrin membrane. A frequent early complication after posterior chamber lens implantation in Japan. Ophthalmol. 1989;96(8):1228-33.

  3. Schimmer BP, Parker KL. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Hardman JG, Limbird LE, Gilman AG, editors. Goodman & Gilman's The Pharmacological Basis of Therapeutics 10th Ed. New York: McGraw-Hill; 2001. p. 1649-77.

  4. Sanders DR, Kraff M. Steroidal and nonsteroidal anti-inûammatory agents. Effect on postsurgical inûammation and blood-aqueous humor barrier breakdown. Arch Ophthalmol. 1984;102(10):1453-6.

  5. Korenfeld M. Diûuprednate: changing the landscape of ocular pharmacology. Expert Rev Ophthamol. 2008;3(6):619-25.

  6. Agency for Healthcare Research and Quality (AHRQ). EPC Evidence Reports [Internet]. Rockville: AHRQ. [actualizada 2013 ene 1; citada 2013 feb 5]. Disponible en: http://www.ahrq.gov/clinic/epcindex.htm#methodology

  7. Bikowski J, Pillai R, Shroot B. The position not the presence of the halogen in corticosteroids inûuences potency and side effects. J Drugs Dermatol. 2006;5(2):125-30.

  8. Yamaguchi M, Yasueda S, Isowaki A, Yamamoto M, Kimura M, Inada K, et al. Formulation of an ophthalmic lipid emulsion containing an anti-inûammatory steroidal drug, diûuprednate. Int J Pharmaceutics. 2005;301(1-2):121-8.

  9. Sweetana S, Akers MJ. Solubility principles and practices for parenteral drug dosage form development. PDA J Pharm Sci Technol. 1996;50(5):330-42.

  10. Dicken CM, Rossi TM, Rajagopalan N, Ravin LJ, Sternson LA. A study of the chemical stability of amphotericin B in N-dimethylacetamide. Int J Pharmaceutics.1988;46(3):223-9.

  11. Loftsson T, Petersen DS. Cyclodextrin solubilization of ETH-615, a zwitterionic drug. Drug Dev Ind Pharm. 1998;24(4):365-70.

  12. Álvarez Núñez FA, Yalkowsky SH. Solubilization of diazepam. J Pharm Sci Technol. 1998;52(1):33-6.

  13. Deicke A, Süverkrup R. Dose uniformity and redispersibility of pharmaceutical suspensions. I: quantiûcation and mechanical modeling of human shaking behaviour. Eur J Pharm Biopharm. 1999;48(1):225-32.

  14. Diestelhorst M, Kwon KA, Süverkrup R. Dose uniformity of ophthalmic suspensions. J Cataract Refract Surg. 1998;24(5):672-7.

  15. Vandamme TF. Microemulsions as ocular drug delivery systems: recent developments and future challenges. Prog Retin Eye Res. 2002;21(1):15-34.

  16. Koycha M, Rochat MH, Verain A. Physico-chemical stability of emulsions: application to mixtures for parenteral nutrition. J Pharm Belg. 1988;43(6):413-24.

  17. Tamilvanan S, Benita S. The potential of lipid emulsion for ocular delivery of lipophilic drugs. Eur J Pharm Biopharm. 2004;58(2):357-68.

  18. Fujino A, Ohtu S, Shibata K. Studies on the metabolic fate of diûuprednate (DFBA). 3. Metabolism in rats and rabbits after subcutaneous administration. Pharmacometrics. 1985;29(2):713-23.

  19. Tajika T, Shirasaki Y, Kimura M. Ocular distribution and metabolism after instillation of diûuprednate ophthalmic emulsion in rabbits. Presented in 2007 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Poster B744, Program 2654. Fort Lauderdale, FL, USA, 6-10 May 2007.

  20. Yasueda S, Kimura M, Ohtori A. Analysis of an anti-inûammatory steroidal drug, diûuprednate, in aqueous humor by combination of semi-micro HPLC and column switching method. J Pharm Biomed Anal. 2003;30(2):1735-42.

  21. Sakaki H, Mito C, Nemoto S. Preclinical toxicity of diûuprednate ophthalmic emulsion. Presented in 2007 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Poster B743, Program 2653. Fort Lauderdale, FL, USA, 6- 10 May 2007.

  22. Inoue J, Yamaguchi M, Sakaki H. Preclinical pharmacokinetics of diûuprednate ophthalmic emulsion. Presented in 2007 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Poster B741, Program 2651. Fort Lauderdale, FL, USA, 6-10 May 2007.

  23. Kida T, Takahaski H, Tsuzuki M. Difluprednate emulsion inhibits postoperative inûammation in rabbit paracentesis model. Presented in 2007 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Poster B745, Program 2655. Fort Lauderdale, FL, USA, 6-10 May 2007.

  24. Okumura A, Tsuzuki M, Wad T. Efûcacy of diûuprednate ophthalmic emulsion in preclinical studies of uveitis The 2007 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Poster B742, Program 2652. Fort Lauderdale, FL, USA, 6-10 May 2007.

  25. Senju Pharmaceutical Co., Ltd., Osaka, Japan. Phase I clinical study of diûuprednate: single instillation. Mar 1999. Data on ûle.

  26. Senju Pharmaceutical Co., Ltd., Osaka, Japan. Phase I clinical study of diûuprednate: repeated instillation. Mar 1999. Data on ûle.

  27. Senju Pharmaceutical Co., Ltd., Osaka, Japan. Phase IIa clinical study of diûuprednate 0.002% and 0.05% in the treatment of postoperative inûammation. Feb 2002. Data on ûle.

  28. Senju Pharmaceutical Co., Ltd., Osaka, Japan. Phase IIb clinical study of diûuprednate 0.05% vs betamethasone 0.1% in the treatment of postoperative inûammation. Apr 2004. Data on ûle.

  29. Ohji M, Tano Y, Hida T. Efûcacy and safety results of a phase III study of diûuprednate ophthalmic emulsion 0.05% in postoperative inflammation. Presented in 2007 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Poster B807, Program 3903. Fort Lauderdale, FL, USA, 6-10 May 2007.

  30. Korenfeld MS, Silverstein SM, Cooke DL, Vogel R, Crockett RS. Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain. J Cataract Refract Surg. 2009;35(1):26-34.

  31. Ohno S, Mochizuki M, Usui M. A phase III noninferiority study of diûuprednate ophthalmic emulsion 0.05% in the treatment of anterior uveitis. Presented in 2007 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Poster B808, Program 3904. Fort Lauderdale, FL, USA, 6-10 May 2007.

  32. Mochizuki M, Ohno S, Usui M. A phase III open-label clinical study of diûuprednate ophthalmic emulsion 0.05% in the treatment of severe refractory anterior uveitis. Presented in 2007 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Poster B809, Program 3905. Fort Lauderdale, FL, USA, 6-10 May 2007.

  33. Sirion Therapeutics, Inc. Tampa, FL. A phase III multicenter, randomized, doublemasked study of the safety and efûcacy of diûuprednate 0.05% ophthalmic emulsion compared to prednisolone acetate 1% ophthalmic suspension in the treatment of endogenous anterior uveitis. Dec 2008. Data on ûle.

  34. Armaly MF. Effect of corticosteroids on intraocular pressure and ûuid dynamics I. The effect of dexamethasone in the normal eye. Arch Ophthalmol. 1963;70(4):482-91.

  35. Armaly MF. Effect of corticosteroids on intraocular pressure and ûuid dynamics II. The effect of dexamethasone in the glaucomatous eye. Arch Ophthalmol. 1963;70(4):492-99.

  36. Baudouin C. Allergic reaction to topical eyedrops. Curr Opin Allergy Clin Immunol. 2005;5(5):459-63.

  37. Price F. Do you welcome BAK? Weighing the toxicity risk. Optometric Management [Internet]. 2004 [citado 2012 dic 14];16(2):[aprox. 4 p.]. Disponible en: http://www.optometric.com/article.aspx?articleZ71020

  38. Dart J. Corneal toxicity: the epithelium and stroma in iatrogenic and factitious disease. Eye. 2003;17(8):886-92.

  39. Yee RW. The effect of drop vehicle on the efûcacy and side effects of topical glaucoma therapy: a review. Curr Opin Ophthalmol. 2007;18(2):134-9.

  40. Negi AK, Browning AC, Vernon SA. Single perioperative triamcinolone injection versus standard postoperative steroid drops after uneventful phacoemulsiûcation surgery: Randomized controlled trial. J Cataract Refract Surg. 2006;32(3):468-74.

  41. Diederich S, Scholz T, Eigendorff E, Bumke-Vogt CH, Quinkler M, Exner P, et al. Pharmacodynamics and pharmacokinetics of synthetic mineralocorticoids and glucocorticoids: receptor transactivation and prereceptor metabolism by 11 betahydroxysteroid- dehydrogenases. Horm Metab Res. 2004;36(6):423-9.

  42. Dunne JA, Jacobs N, Morrison A, Gilbert DJ. Efûcacy in anterior uveitis of two known steroids and topical tolmetin. Br J Ophthalmol. 1985;69(2):120-5.

  43. American Medical Association. Statistics on Blindness and Blinding Diseases in the United States [Internet]. The University of Washington Department of Ophthalmology; c19972004 [actualizada 2013 ene 1; citada 2013 feb 5]. [aprox. 4 pantallas]. Disponible en: http://depts.washington.edu/ophthweb/statistics.html

  44. Frequently Asked Questions [Internet]. American Uveitis Society; c2002 [citada 2013 feb 5]. Disponible en: http://www.uveitissociety.org/pages/faq.html

  45. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 1990;150(9):1881-4.

  46. Nakano S, Yamamoto T, Kirii E, Abe S, Yamashita H. Steroid eye drop treatment (difluprednate ophthalmic emulsion) is effective in reducing refractory diabetic macular edema. Graefe's Arch Clin Exp Ophthamol. 2010;248(6):805-10.




2020     |     www.medigraphic.com